-
In-depth review
-
Korean J Med. 2026;101(2):70-76. Published online April 1, 2026.
DOI: https://doi.org/10.3904/kjm.2026.101.2.70
- 조기 유방암의 전신 치료
-
안희경
-
성균관대학교 의과대학 삼성서울병원 혈액종양내과
- Systemic Treatment for Patients with Early-Stage Breast Cancer
-
Hee Kyung Ahn
-
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Corresponding author: Hee Kyung Ahn ,Tel: +82-2-3410-1794, Email: hkahn.onco@gmail.com
- Received: January 7, 2026; Revised: March 2, 2026 Accepted: March 10, 2026.
-
߽ɾ :유방암; 보 조 항암 화학 요법; 면역관문억제제; 선행 요법
- Abstract
- Breast cancer is the most common malignancy among women in Korea and its incidence is rapidly increasing. Perioperative systemic treatment plays a critical role in achieving a cure for early-stage breast cancer. With the introduction of novel systemic agents, treatment outcomes have improved and perioperative strategies have become increasingly diverse. In addition to conventional anthracycline- and taxane-based chemotherapies, targeted therapies and/or immunotherapy have expanded the options to both neoadjuvant and adjuvant settings. Increasing numbers of (neo) novel adjuvant agents and post-neoadjuvant treatments have demonstrated survival benefits, supporting more individualized perioperative treatment approaches in patients with early breast cancer.
Keywords :Breast neoplasms, Adjuvant chemotherapy, Immunotherapy, Neoadjuvant therapy
 |
 |
